Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose decitabine for early relapse of MDS/AML after allogeneic hematopoietic stem cell transplantation
ChiCTR-OPN-17012796Phase 4Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Xinqiao Hospital. Primary endpoint: Complete remission. Started Oct 2017; status: recruiting.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR-OPN-17012796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-17012796.